Please assess the completion status of the following clinical trial:

Trial Title: Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults from 18 to 80 years old with an estimated alcohol intake of:~  * 14 units of alcohol per week during the month before hospitalisation for men aged 18 to 64~ * 7 units of alcohol per week during the month before hospitalisation for women or men older than 65.~AND Intubated, ventilated with an expected duration of mechanical ventilation\> 24 hours at least~Exclusion Criteria:~* Hospitalization \> 7 days~* Baclofen administration before ICU admission (personal treatment or single administration)~* Pregnancy~* Porphyria~* Burned on ICU admission~* Personal treatment including Gamma-hydroxybutyric acid (Alcover/Xyrem)~* Recent stroke or subarachnoid haemorrhage or head trauma with radiological evidence~* Recent or old paraplegia or tetraplegia~* Cardiac arrest with resuscitation manoeuvres before or after ICU admission~* Contraindication to Enteral drug administration for longer than 24 hours~* Lack of social protection~* Hypersensitivity to Baclofen~* Coeliac disease~* Refractory epilepsy~* Dementia, schizophrenia, Bipolar disorder or severe depression.~* Parkinson's disease~* Health care limitation owing to pejorative prognosis~* Tracheotomy on ICU admission~* Patients under guardianship or trusteeship~* Patients already enrolled in interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BACLOFEN (Type: EXPERIMENTAL): patient will receive baclofen caps
- PLACEBO (Type: PLACEBO_COMPARATOR): patient will receive placebo caps (lactose)

Based on this trial design, predict the completion outcome and termination type (if applicable).